Company news
Adalta Ltd. (ASX:1AD) news
Adalta Ltd. news releases on 6ix. Latest, Dec 14, 2021: Voluntary Suspension
Press releases — page 3
Voluntary Suspension
December 13, 2021
Inhaled AD-214 passes first development milestone
December 8, 2021
AGM presentations & first iCAR-T data
November 28, 2021
Second US patent for AD-214
November 17, 2021
BTB funding transferred to AD-214 inhalation program
October 6, 2021
New pre-clinical data presented at Boston conference
September 26, 2021
Corporate overview and IRD Invest 2021 presentation
September 20, 2021
$4.0M Non-Dilutive Financing with Victorian Government
September 19, 2021
Carina collaboration webinar presentation
August 25, 2021
CAR-T collaboration with Carina Biotech
August 23, 2021
Webinar and presentation on AD-214 strategy
July 19, 2021
AD-214 pathway to IPF efficacy studies
July 18, 2021
AdAlta secures AD-214 resupply
July 1, 2021
R&D Tax Incentive Facility
June 24, 2021
GE Healthcare collaboration advances to next stage
May 23, 2021
AdAlta granted Japanese patent for AD-214
May 18, 2021
Mutiple Dose Part Of Ad-214 Phase I Trial Commenced
April 18, 2021
Investor briefing-AD-214 top line single dose safety results
March 9, 2021
Appendix 4D and Interim Financial Report
February 25, 2021
FDA Orphan Drug Designation for AD-214
February 23, 2021
Phase I HV extension to explore encouraging results
December 13, 2020
AGM Presentation
November 25, 2020
AusBiotech presentation including Phase I status update
October 26, 2020
Investor Presentation - BIO investor forum
October 9, 2020
GE Healthcare collaboration progresses
September 20, 2020
Non-renounceable Rights Issue Offer
August 18, 2020
Placement and Rights Offer
August 10, 2020
Investor presentation including future milestones
July 29, 2020
First participants treated in AD-214 Phase I trial
July 23, 2020
Supportive US FDA pre-IND meeting results for AD-214
July 19, 2020
AdAlta receives approval to commence AD-214 Phase I trial
June 9, 2020
Business update and COVID-19 response
March 30, 2020
Board changes and R&D Tax Incentive advance received
March 26, 2020
Investor Briefing - Strategic Plan
March 2, 2020
AD-214 effective in gold standard pre-clinical animal model
March 1, 2020
Appendix 4C - quarterly
January 30, 2020
AdAlta Granted US Patent for AD-214
January 29, 2020
AD-214 Phase I strategy and timing update
January 13, 2020
AdAlta awarded Biomedical Translation Bridge Funding
December 12, 2019
GLP Toxicology study results
October 28, 2019
Tim Oldham Appointed as Chief Executive Officer
October 8, 2019
Receipt of R&D Tax Incentive
September 17, 2019
AdAlta secures licensing deal with GE Healthcare
September 15, 2019
Executive team changes
August 11, 2019
GLP toxicology study commences
July 15, 2019
Entitlement Offer Results and Shortfall Notification
June 14, 2019
Completion of Capital Raise - $5 million
May 23, 2019
AD-214 manufacturing update
May 2, 2019
Manufacturing update
January 28, 2019
Appendix 4C - Quarter ended 30 September 2018
October 16, 2018